Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2016-11-25, 09:21:23 | version 1.38.0
By St. Renatus Staff n St. Renatus is excited to announce that Kovanaze™ (tetracaine HCl and oxymetazoline HCl) nasal spray, the first FDA-approved, needle-free, regional dental anesthesia for the maxillary arch, is now available for order. TheKovanazeproductlaunchcoin- cidedwiththeAmericanDentalAsso- ciation’s annual meeting in Denver in October. Now, you can visit booth No. 5040 here in New York to place your order, Approved by the U.S. Food and Drug Administration (FDA) on June 29, Kovanaze is indicated for regional anesthesia when performing a restor- ative procedure on teeth #4–#13 and A-J in adults and children weighing more than 40 kg. In Phase 3 clinical trials, use of Kovanaze in the anterior maxillary region during restorative procedures resulted in 96 percent efficacy in teeth #5–#12 and 63 percent efficacy in teeth #4 and #13. Additionally, patientsmaynotexperiencethesame sensation of numbness or tingling of the lips and cheeks associated with injectable dental anesthetics. “It is a significant moment in den- tistry as a new delivery method for pain management is now available,” said Steve Merrick, St. Renatus, chief executive officer. “For decades, nee- dles have been the mainstay for deliv- ering dental anesthesia; now dentists have the option to offer patients a regional anesthesia via a nasal spray for restorative procedures in the smile zone.” exhibitors 18 Greater New York Dental Meeting — Nov. 27, 2016 Kovanaze nasal spray launched Ad Place your order for the new product at booth No. 5040 Here in New York To learn more about Kovanaze or to place an order, please visit booth No. 5040, contact your dental dealer, or calltheKovanazeSupportLineat(800) 770-9400. 5 Kovanaze nasal spray is now available to order here at the Greater New York Dental Meetng. (Photo/Provided by St. Renatus)